



for **immunotherapies & innovations
infectious Diseases**

7th Congress – 22 & 23 November 2023 - Lyon, France



LYONBIOPOLE
AUVERGNE-RHONE-ALPES

Post-Event Report

OUR STORY

The emergence of new infectious diseases, the re-emergence of “old” infectious diseases, the rise of antibacterial resistance and the difficulty to come out with a new pipeline of new antimicrobial compounds leads to consider the potential of non-conventional approaches, such as immunotherapies as new therapies.

Already on the seventh edition, the **I4ID congress** started on 2017 and the aim was to develop an exclusive conference dedicated to immunotherapies and infectious diseases, something that never existed before. In 2019, The thematic was enlarged to include, with the immunotherapies, all the innovations being developed to fight infectious diseases. Last year, regarding the unique sanitary situation we were going through, we had decided it was imperative to include on this edition program the COVID-19 thematic.

I4ID is co-organized by **MabDesign**, the association who the aim is to support and federate the french industrial sector of biotherapy (www.mabdesign.fr) and **Lyonbiopôle**, the healthcare cluster of the Auvergne-Rhône-Alpes region (<https://lyonbiopole.com>). These two emblematic health stakeholders have brought together, for two days, experts from around the world to combine approaches and strengths to innovate in the fields of infectious diseases and immunotherapy.

From 2017



1250+ attendees



220+

High-profile speakers



390+

Different organizations present



980+

B2B meetings

FOCUS IN 2023



immunotherapies & innovations for infectious diseases

7th Congress – 22 & 23 November 2023 - Lyon, France

The **I4ID2023** program included 5 tracks with keynote lectures, pitch talks and industrial talks covering the latest developments and highest innovative projects in the field. Furthermore, it was possible to set up, through an online platform, business meetings during both days (partnering).


The topics covered during this congress were:

- Alternative to antibiotics
- Immunotherapies
- Innovative vaccines
- Diagnostic, prognostic and clinical biomarkers
- EU and international initiatives supporting the value chain of countermeasures against infectious diseases from research to access (roundtable)

WHO ATTENDED IN 2023?

KEY FIGURES

- ✓ 270+ participants from different countries
- ✓ 110+ different organizations present
- ✓ 260+ BtoB meetings took place
- ✓ 44 High-profile Speakers
- ✓ 24 Sponsors & Exhibitors



WHO ATTENDED IN 2023?

COMPANIES WHICH ATTENDED :

ACROBIOSYSTEMS | ADERLY / Invest in Lyon | Adjuvatis | Advanced Instruments | Affilogic | Africa CDC | AIS Biotech | ALPIONER Therapeutics | AltraBio SAS | AM-Biotech Consulting | ANRS | Maladies infectieuses émergentes | ARXUM | AstraZeneca | AUROBAC THERAPEUTICS | AZENTA LIFE SCIENCES | BACFLY CNRS UAR3426 Biocampus | BCV care | BIOASTER | BioKryo | BioMerieux | BioNTech SE | Bio-Techne | BIOTEM Custom antibodies & services | Biothelis | Boehringer-Ingelheim Animal Health | bYoRNA | CAPEVAL PHARMA | CEA-LETI | CeGaT GmbH | Centre International de Recherche en Infectiologie (CIRI) | CEPI | Cézame Connexions | Charles River Laboratories | CHU Limoges | CIRAD/ UMR Astre | CNRS | CRODA | CYBERNANO | Cynbiose | Deeptope | Department of Internal Medicine, Radboud University Medical Center | DREETS Auvergne-Rhône-Alpes | EFPIA/Vaccines Europe | Eligo Bioscience | EPIMOD | Epynext Therapeutics | ERBC | ESSEC Business School | European Health Emergency Preparedness and Response Authority (HERA) | European Molecular Biology Laboratory, Grenoble | Evotec | FABENTECH | Fab'entech | Faculty of medicine of Geneva | Floralis | Francis Crick Institute | Gavi | GeNeuro SA | Greiner Bio-One | GRIPA | GSK Vaccines | Hospices Civils de Lyon / International Center for Infectiology Research (CIRI) | ICTA | Imcheck Therapeutics | Imperial College London | Innovative Health Initiative (IHI) | Institut Mérieux | Institut Pasteur | Integrated DNA Technologies (IDT) | INTERNATIONAL VACCINE INSTITUTE (IVI) | KyooBe Tech GmbH | LA GAZETTE DU LABORATOIRE | Lyon I University | Mabqi | MAYAKARE - EVALUATION & CONSEILS SCIENCES DE LA VIE | Meddenovo Drug Design | Merck Life Science | MICHADVICES | Miltenyi Biotec | MOLSID | New England Biolabs France | Nicoya | OLINK PROTEOMICS | Oncodesign Services | opial | Osivax | PASREL-Imagerie / CEA | PHAXIAM THERAPEUTICS | Pherecydes Pharma | PLANTIBODIES | Promega | PROTEIGENE | Quantoom Biosciences | RD-BIOTECH | Reckonect SAS | Revvity | Sanofi | Seqens | SGPI | SGS Vitrology | SinoBiological | SPIKIMM | Stemlnov | Tebubio | ten23 health AG | Texcell | The London School of Hygiene & Tropical Medicine (LSHTM) | TRANSGENE | Turing Biosystems | Ultrace DP & SpikImm | Université de Strasbourg | University Lyon 1 | Uppsala University | VALNEVA | VDH Consulting | VIBIOSPHEN | VOXCAN | Yubsis |

AGENDA 2023

DAY 1

Wednesday, November 22nd 2023

9h30 Registration & Welcome coffee

10h00 Welcome Address

10h05 **Opening lectures** - Lima & Mexico room

Chaired by Daniel Larocque, Sanofi

CEPI's approach to vaccine libraries and rapid response platforms - an integral part to its 100 Days Mission

Martina Ochs

Project Leader

CEPI, Norway

Title to be defined

Sefonias Kifle Tessema

Program lead for pathogen genomics

Africa CDC, Ethiopia

Trained immunity: from pathophysiology to therapeutic target

Mihai Netea

Head of the division of Experimental Medicine

Radboud University Medical Center, Netherlands

11h35 **France2030 initiatives** - Lima & Mexico room

Accelerating innovation in the field of emerging diseases: the "Biocluster Français pour l'Innovation en Infectiologie (BCF2I)" project

Bruno Lina

Head of Department

Laboratoire de Virologie, Centre national de référence virus des infections respiratoires & Centre national de référence entérovirus et paréchovirus, France

Developing innovative therapies to cure hepatitis B virus infections: from basic science to clinical applications

Fabien Zoulim

Head of the Hepatology Department

Hospices Civils de Lyon & Head of the Viral Hepatitis Research Laboratory - INSERM Unit 1052 - France

12h15 Lunch - Poster presentation - B2B - Exhibition Hall

14h00 **Track 1: Alternatives to current antibiotics** - Lima & Mexico room

Chaired by Sébastien Coyne, Aurobac Therapeutics and Ana Antunes, MabDesign

Challenges of phage therapy in 2023: shared insights from key French private and public players

Frédéric Laurent

Co-principal investigator

Hospices Civils de Lyon, Centre International de Recherche en Infectiologie Inserm U1111-UMR CNRS 5308,

ISPB Lyon - Université Lyon 1, France

Cindy Fèvre

Scientific director

Phaxiam, France

In situ targeted mutagenesis of gut bacteria

David Bikard

Head of lab

Pasteur Institute, France

Founder

Eligo Bioscience - France

AGENDA 2023

Incentivizing Novelty in Antibiotic Development

Gosia Majewska

Health and industrial organization economist
ESSEC Business School, France

ENABLE-2: A European Antibacterial Drug Discovery Platform

Anders Karlén

Project coordinator
ENABLE-2
Head of the Department of Medicinal Chemistry
Uppsala University, Sweden

PanHunter - an all-in-one omics data analysis platform

Erik Schliep

Product Manager
Evotec, France

15h40 Coffee break - B2B - Exhibition Hall - Poster presentation

16h20 **Track 2: Immunotherapies** - Lima room 16h20

Chaired by Geneviève Inchauspé, Transgene

Transcriptional signatures reveal the immune response underlying progression and pathogenesis in tuberculosis

Anne O'Garra

Principal Group Leader
Francis Crick Institute, UK

Monoclonal antibodies for prolonged Covid-19 protection in immunocompromised individuals

Cécile Artaud

Therapeutic Area Medical Lead
AstraZeneca, France

Life saving stem cell therapy for septic shock and ARDS 17h20

Julie Hutin

CEO
Stemlnov, France

Securing the supply chain for vaccine adjuvants in the future

Dennis Christensen

Head of Global R&D
Croda, Denmark

Promega: A Partner for Multidisciplinary Infectious Disease Research and Development

Aymeric Morlé

Custom/OEM specialist
Promega

Accelerating drug discovery using advanced protein and an-tibody development platforms

Yu-Chih Lin

Technical Specialist
Sino Biological, Germany

18h00 Poster presentation - Exhibition Hall - Wine & Cheese

Workshop - Mexico room

Translational in vivo imaging for anti-infectious diseases treatment and diagnosis follow up by PASREL-Imagerie

Ali Ait-Ikhlef

Business Development Manager
PASREL-Imagerie

Benoît Delache

R&D engineer in animal experimentation
PASREL-Imagerie

Julien Lemaitre

Clinical veterinarian and Immunologist
PASREL-Imagerie

- Mexico room

Breakthrough Innovation session

Chaired by Mélanie Denizot, Lyonbiopôle

System serology approach on COVID-19 patients' sera reveal specific immune pattern in the heterogeneous population: The COVIDAuRA study

Carla Saade

Phd student
Hospices Civils de Lyon and Centre International de Recherche, France

Fully automated workflow for cytometry data analysis: Evaluating the effects of adjuvant candidates on memory B and T cells in a phase I clinical trial.

Julien Nourikyan

Business Development and Partnerships Manager
Atrabio, France

Limitations of threshold-based decisions in Disease X vaccine clinical trials

Julien Flaig

Epidemiological and health economic simulation modeling
Epimod, France

AGENDA 2023

DAY 2

Thursday, November 23rd 2023

9h00 Welcome coffee

9h30 Keynote lectures - Lima & Mexico room

Chaired by Daniel Larocque, Sanofi

Opportunities and Challenges of AI for Infectious Disease Vaccines and Therapeutics

Saranya Sridhar

Global Head of Clinical Franchise for the mRNA Center and Head of Translational Medicine
Sanofi, United Kingdom

10h30 Coffee break - B2B - Exhibition Hall - Poster presentation

11h00 **Track 3: Diagnostic, prognostic and clinical biomarkers** - Lima room

Chaired by Jean François Litişos, bioMérieux

Biomarkers and AI to develop personalised medicine in sepsis.

Anthony Gordon

Chair in Anaesthesia and Critical Care, NIHR Research Professor & Senior Investigator
Imperial College London, United Kingdom

Endocan, a novel biomarker for pneumonia

Philippe Lassale

Founder
Biothelis, France

Advancing anti-viral and vaccine research with Revvity's fluorescent assays

Mathis Laffenetre

LifeScience Product Leader
Revvity, France

A unique solution for antigens that cannot be detected with classical ELISA in medical diagnostic applications: example for inclusion in clinical trial on long COVID.

Hervé Perron

Chief Scientific Officer
GeNeuro SA, Switzerland

12h00 Lunch - Poster presentation - B2B - Exhibition Hall

14h00 **Track 3: Diagnostic, prognostic and clinical biomarkers** - Lima room

Chaired by Cyril Guyard, Bioaster

Identification by proteomics of infection markers in the skin: application to a direct diagnosis of Lyme borreliosis

Nathalie Boulanger

Medical entomologist & Research group leader
Université de Strasbourg, France

Strategic Partnerships to Address Diagnostic Unmet Needs in Low- and Middle-Income Countries

Philippe Leissner

Head of R&D Diagnostic Programme
BIOASTER, France

Immune profiling of COVID-19 mRNA vaccines in immunocompromised patients

Arnaud Didierlaurent

Professor at the Faculty of Medicine
University of Geneva, Switzerland

11h00 **Roundtable: EU and international initiatives supporting the value chain of countermeasures against infectious diseases from research to access** - Mexico room

Animated by Nadia Khelef, National Acceleration Strategy Emerging Infectious Diseases and CBRN Threats

Marta Tufet Bayona

Head of Policy
GAVI, Switzerland

Anh Wartel

Deputy Director General / Head
IVI Europe Regional Office (IERO) - Sweden

Bangin Brim

Policy Officer Health Threats
European Commission - European Health Emergency Preparedness and Response Authority (HERA), Belgium

Tek-Ang Lim

Scientific officer
Innovative Health Initiative (IHI) - Belgium

14h00 **Breakthrough Innovation session** - Mexico room

Chaired by Fabienne Venet, Hospices Civils de Lyon and Mélanie Denizot, Lyonbiopôle

GlycoFlu, a first-in-class synthetic multivalent sialoside compound with antiviral activity to prevent or treat infections by Influenza viruses

Aurélié Juhem

Chief Executive Officer
AIS biotech, France

Neutralizing and Enhancing Monoclonal Antibodies in SARS-CoV-2 Convalescent Patients: Lessons from Early Variant Infection and Impact on Shaping Emerging Variants

Frédéric Coutant

Associate Professor in Immunology
Hospices Civils de Lyon, France

Inhalable Nanofitin as new therapeutic for direct application in respiratory tract

Sébastien Violet

Scientist
Afflogic, France

New rapid detection of beta-lactamase producing bacteria using fluorogenic probes

Didier Filopon

R&D projects manager

Molsid, France

Recombinant multimeric spike proteins: A promising vaccine against COVID-19

Marianne Figl

Study Director

Voxcan, France

15h00 Coffee break - B2B - Exhibition Hall - Poster presentation

15h30 **Track 4: Innovative vaccines** - Lima & Mexico room

Chaired by Sherif Abouelhadid, London school of Hygiene & Tropical Medicine and Lionel Cupillard, Boehringer Ingelheim Animal Health

Evaluation of vaccination strategies against avian influenza in poultry production networks: comparison of the EVACS tool application in several countries

Claire Hautefeuille

Veterinary & epidemiologist

CIRAD/ UMR Astre, France

Current strategic approaches in the evaluation of vaccines as complementary tools for prevention and control of HPAI

Teshome Mebatsion

Executive Director, Viral Disease Research

Boehringer Ingelheim Santé Animale, France

Multivalent pneumococcal conjugate vaccines: trade-offs of an arms race

Anthony Scott

Epidemiologist

LSHTM, London

KEMRI-Wellcome Trust, Kenya

Recent advancements in the glycoconjugate vaccines field

Francesco Berti

Senior Director

GSK Vaccines, Italy

Clinical update of OVX836, a novel Universal Type A influenza vaccine candidate

Florence Nicolas

Chief Development Officer and Co-Founder

Ostivax, France

17h10 Announcement of next year edition

17h20 End of the Congress

SCIENTIFIC ADVISORY BOARD




Geneviève Inchauspé

Senior Director, R&D Programs
Transgene



Sandra Morel

Director, Research Project Leader, Discovery Performance Unit
GSK Vaccines



Bruno Lina

University Professor and Hospital Practitioner, Director
National Reference Center for respiratory infections virus, VirPath Laboratory, University Lyon 1



Cyril Guyard

Deputy CSO
Bioaster



Sébastien Coyne

Senior Project Leader, Discovery Research
Aurobac Therapeutics



Laure Delhon

Events Manager and Communication
MabDesign



Natalia Bomchil

Innovation Director
Lyonbiopôle



Daniel Larocque

Microbiology-Immunology Platform Manager
Sanofi



Michel Perez

Head of Development Of Innovation Department
Pasteur Institute



Jean François Litjens

Scientific and medical Expert
Open innovation and Partnership
bioMérieux

SCIENTIFIC ADVISORY BOARD



Fabienne Venet

University professor, Hospital practitioner

Hospices Civils de Lyon



Frédéric Reynard

Global Project Leader

Boehringer Ingelheim



Hervé Raoul

Directeur adjoint


ANRS | Maladies infectieuses émergentes



Robbert van der Most

Vice President Translational Science

BioNTech



Sherif Abouelhadid

Head at Biological and Pharmacological Pillar at Antimicrobial Resistance Centre

London school of Hygiene & Tropical Medicine



Nadia Khelef

Coordinator

National Acceleration Strategy
Emerging Infectious Diseases and
CBRN Threats, France

General investment secretary office

Health Innovation Agency, France

ORGANISATION COMMITTEE



Laure Delhon
Events Manager and
Communication
MabDesign



Ana Antunes
Head of Scientific Events
and Communication
MabDesign



Natalia Bomchil
Innovation Director
Lyonbiopole



Sally Peschiera
Events Manager
Lyonbiopole



Stéphanie Pelège
Head of
Communication
Lyonbiopole

2023 SPONSORS

Platinum Sponsor

sanofi

Silver Sponsor



Bronze Sponsors

biotechne®


CRODA



revvity

SB SinoBiological

2023 EXHIBITORS



2023 PARTNERS

Supporting partners



Institutional and Media partners





I4ID



immunotherapies & innovations
for **Infectious Diseases**

8th Congress 2024

27-28 November 2024 – LYON, FRANCE

For more information,
Please contact Laure Delhon – MabDesign at:
laure.delhon@mabdesign.fr or tel. 0033 (0)4 78 02 39 92

Follow Us



I4IDCongress



I4IDcongress

#I4ID2024